Traded Oct 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Traded Sep 21, 2026 · Filed Sep 23, 2026
The CEO of United Therapeutics sold $1.13M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,133,694
Shares × reported transaction price
47 days after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $493.10 on Sep 21, 2026, 19% above its 52-week low and 17% below its high, after an 8% drop over the previous 30 trading days
52-week range $415.34 (Oct 28, 2025) to $596.76 (May 6, 2026), 43% of the way up, from 241 adjusted closes. 30 trading days earlier: $538.84 on Aug 7, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +10.7% | −0.7% | +11.4% |
Past results only. Not a forecast.
Traded Oct 5 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$269K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$486K of United Therapeutics
Scheduled in advance